

CHAPTER 1: INTRODUCTION	1
STUDY GOAL AND OBJECTIVES	1
REASONS FOR DOING THE STUDY	1
INTENDED AUDIENCE.....	1
SCOPE OF REPORT	2
METHODOLOGY	2
INFORMATION SOURCES	2
AUTHOR'S CREDENTIALS	3
RELATED BCC PUBLICATIONS	3
BCC ONLINE SERVICES.....	3
DISCLAIMER	4
 CHAPTER 2: SUMMARY	 5
SUMMARY	5
<i>SUMMARY TABLE U.S. MARKET FOR SOLID ORGAN AND TISSUE TRANSPLANTATION, THROUGH 2013 (\$ MILLIONS)</i>	6
<i>SUMMARY FIGURE U.S. MARKET FOR SOLID ORGAN AND TISSUE TRANSPLANTATION, 2007-2013 (\$ MILLIONS)</i>	6
 CHAPTER 3: INDUSTRY OVERVIEW.....	 7
INDUSTRY OVERVIEW	7
HISTORY OF TRANSPLANTATION.....	8
TISSUE TYPING	8
IMMUNOSUPPRESSION	9
Newer Immunosuppressive Drugs.....	9
PRESERVATION	10
GOVERNMENT REIMBURSEMENT	11
THE TRANSPLANTATION PROCESS.....	11
PREPARATION	11
SURGERY	12
RECUPERATION	12
MAINTENANCE.....	13
IMPORTANCE OF THE INDUSTRY.....	13
ORGANS	13
<i>TABLE 1 U.S. ORGAN TRANSPLANTS: AVERAGE FIRST YEAR COST, NUMBER OF PROCEDURES AND VALUE BY TYPE OF ORGAN TRANSPLANT, THROUGH 2013 (\$ MILLIONS)</i>	14
KIDNEY.....	14
<i>TABLE 2 LEADING U.S. KIDNEY TRANSPLANT PROGRAMS BY TOTAL NUMBER OF PROCEDURES PERFORMED IN 2007</i>	15
LIVER	15

<i>TABLE 3 TOP FIVE U.S. LIVER TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007</i>	16
HEART.....	16
<i>TABLE 4 TOP FIVE U.S. HEART TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007</i>	17
LUNG.....	17
<i>TABLE 5 TOP FIVE U.S. LUNG TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007</i>	18
INTESTINE.....	18
<i>TABLE 6 TOP FIVE U.S. INTESTINE/SMALL BOWEL TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007</i>	19
PANCREAS	19
<i>TABLE 7 TOP FIVE U.S. PANCREAS TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007</i>	20
TISSUES	20
DRIVERS IN THE MARKET	20
<i>TABLE 8 TISSUE GRAFTING IN THE U.S. BY TISSUE TYPE, THROUGH 2013 (MILLION PROCEDURES)</i>	21
<i>FIGURE 1 U.S. MARKET FOR TISSUE GRAFTING PROCEDURES BY TYPE, 2007-2013 (MILLION PROCEDURES)</i>	21
CORNEA.....	22
BLOOD STEM CELLS.....	22
BONE ALLOGRAFTS.....	23
HEART VALVES.....	23
VASCULAR TISSUE	23
SKIN AND COLLAGEN	24
Applications	24
WAITING LISTS OUTPACE DONATIONS.....	24
<i>TABLE 9 PATIENTS ON U.S. WAITING LISTS AT THE END OF THE YEAR BY TYPE OF ORGAN TRANSPLANT, 2003–2006</i>	25
TRENDS IN U.S. LIVING AND CADAVERIC DONATIONS	25
<i>TABLE 10 TRENDS IN U.S. LIVING AND CADAVERIC DONATIONS, THROUGH 2013</i>	26
TRENDS IN TRANSPLANTATION OF ALL ORGANS.....	26
<i>TABLE 11 U.S. ORGAN TRANSPLANTS, THROUGH 2006 (NUMBER OF PROCEDURES)</i>	26
INTERNATIONAL TRENDS	27
<i>TABLE 12 NUMBERS OF DONATED CADAVERS BY REGION, 2003– 2006</i>	27
LIMITED SUPPLY CURTAILS TRANSPLANTATIONS.....	28
Living Donor Programs	28
KEY FACTORS IN INDUSTRY GROWTH	28
Reducing Demand.....	28
Patient Survival Rates	29

<i>TABLE 13 ONE-YEAR AND FIVE-YEAR PATIENT SURVIVAL RATES, BY ORGAN FOR TRANSPLANTS PERFORMED, 1997–2004 (%)</i>	29
<i>TABLE 14 ONE-YEAR AND FIVE-YEAR GRAFT SURVIVAL RATES, BY ORGAN FOR TRANSPLANTS PERFORMED, 1997–2004 (%)</i>	29
<i>TABLE 14 (CONTINUED)</i>	30
<i>TABLE 15 NUMBER OF PEOPLE IN THE U.S. LIVING WITH A FUNCTIONING TRANSPLANT BY TYPE, 2000–2005*</i>	30
Organ Substitutes.....	30
Organs from Animals: Xenotransplantation	30
Organ Primordia	31
Nuclear Transfer to Eliminate the Rejection Gene	32
Porcine Endogenous Retrovirus	32
ARTIFICIAL ORGANS	33
CELLULAR TRANSPLANTS.....	33
KEY FACTORS INHIBITING GROWTH.....	34
LACK OF DONORS	34
ALTERNATIVE THERAPIES	34
CULTURAL STIGMAS	34
CHAPTER 4: GOVERNMENT REGULATIONS	35
GOVERNMENT REGULATIONS	35
THE MEDICARE DRUG DISCOUNT CARD PROGRAM, MEDICARE DRUG BENEFITS, AND TRANSPLANT PATIENTS	36
<i>TABLE 16 IMMUNOSUPPRESSIVE DRUGS CURRENTLY COVERED BY MEDICARE*</i>	36
<i>TABLE 17 MEDICARE IMMUNOSUPPRESSIVE DRUG COVERAGE OVERVIEW</i>	37
CHAPTER 5: TRANSPLANTATION PRODUCTS AND PHARMACEUTICALS.....	38
HLA TISSUE TYPING	38
THE WORLD MARKET FOR HLA TYPING	39
<i>TABLE 18 WORLD MARKET FOR HLA TYPING, THROUGH 2013 (\$ MILLIONS)</i>	39
THE U.S. MARKET FOR HLA TYPING	39
<i>TABLE 19 U.S. MARKET FOR HLA TYPING, THROUGH 2013 (\$ MILLIONS)</i>	40
ORGAN PRESERVATION PRODUCTS.....	40
<i>TABLE 20 PRESERVATION TIME FOR TRANSPLANTED ORGANS (HOURS)</i>	41
Custodiol	41
Warm Organ Perfusion	41
IMMUNOSUPPRESSION	42
<i>TABLE 21 IMMUNOSUPPRESSIVE DRUGS APPROVED IN THE U.S. BY CLASS</i>	43

Antibodies.....	43
<i>TABLE 22 ANTIBODY PRODUCTS FOR TREATMENT OF ORGAN TRANSPLANT REJECTION.....</i>	<i>44</i>
<i>TABLE 23 COMMONLY USED INTRAVENOUS ANTIBODY IMMUNOSUPPRESSIVE DRUGS.....</i>	<i>44</i>
<i>TABLE 23 (CONTINUED).....</i>	<i>45</i>
OKT-3	45
Zenapax	45
Simulect.....	46
Campath/MabCampath	46
Polyclonal Antibody Products.....	46
Atgam.....	46
Thymoglobulin.....	47
The Market for Antibody Products to Treat Organ Transplant Rejection.....	48
<i>TABLE 24 GLOBAL MARKET FOR ANTIBODY PRODUCTS TO TREAT ORGAN TRANSPLANT REJECTION, THROUGH 2013 (\$ MILLIONS).....</i>	<i>48</i>
<i>FIGURE 2 GLOBAL MARKET FOR ANTIBODY PRODUCTS USED IN ORGAN TRANSPLANTATION, 2007-2013 (\$ MILLIONS).....</i>	<i>48</i>
Antiproliferative Agents.....	49
Azathioprine.....	49
CellCept.....	49
Myfortic	49
<i>TABLE 25 GLOBAL MARKET FOR ANTIPROLIFERATIVE AGENTS TO TREAT ORGAN TRANSPLANT REJECTION: WORLDWIDE SALES, THROUGH 2013 (\$ MILLIONS)</i>	<i>49</i>
<i>FIGURE 3 GLOBAL MARKET FOR ANTIPROLIFERATIVE AGENTS, 2007-2013 (\$ MILLIONS).....</i>	<i>50</i>
Calcineurin Inhibitors	50
Tacrolimus.....	50
Cyclosporine	51
Generic Cyclosporine	52
<i>TABLE 26 GLOBAL MARKET FOR CALCINEURIN INHIBITORS TO TREAT ORGAN TRANSPLANT REJECTION: WORLDWIDE SALES, THROUGH 2013 (\$ MILLIONS).....</i>	<i>52</i>
<i>FIGURE 4 GLOBAL MARKET FOR CALCINEURIN INHIBITORS, 2007- 2013 (\$ MILLIONS).....</i>	<i>53</i>
Source: BCC Research	53
M-TOR Inhibitors	53
Certican	53
Rapamune.....	54

<i>TABLE 27 GLOBAL MARKET FOR M-TOR INHIBITORS TO TREAT ORGAN TRANSPLANT REJECTION: WORLDWIDE SALES, THROUGH 2013 (\$ MILLIONS)</i>	54
Concern About Generics	54
<i>TABLE 28 U.S. SALES OF IMMUNOSUPPRESSIVES BY DRUG CATEGORY, THROUGH 2013 (\$ MILLIONS)</i>	55
<i>FIGURE 5 U.S. SALES OF IMMUNOSUPPRESSIVES, BY CATEGORY, THROUGH 2013 (\$ MILLIONS)</i>	56
IMMUNOSUPPRESSIVE AGENTS IN DEVELOPMENT.....	56
<i>TABLE 29 SELECTED IMMUNOSUPPRESSIVE AGENTS IN PHASE 1 OR LATER DEVELOPMENT</i>	56
<i>TABLE 29 (CONTINUED)</i>	57
TOLERANCE	57
Antisense Therapy.....	57
Costimulation	58
Chimerism.....	59
USUAL ANTI-REJECTION DRUG PROTOCOLS	59
<i>TABLE 30 COMMON IMMUNOSUPPRESSIVE REGIMENS</i>	60
INDUCTION THERAPY.....	60
<i>TABLE 31 IMMUNOSUPPRESSANT USE FOR INDUCTION, BY ORGAN IN 2006 (%)</i>	61
MAINTENANCE THERAPY	61
<i>TABLE 32 IMMUNOSUPPRESSANT USE FOR MAINTENANCE AT DISCHARGE BY ORGAN IN THE U.S., 2006 (%)</i>	62
<i>TABLE 33 IMMUNOSUPPRESSANT USE FOR MAINTENANCE AT 1-YEAR POST-TRANSPLANT BY ORGAN IN U.S., 2006 (%)</i>	63
REJECTION THERAPY.....	64
Risks Associated with Immunosuppressive Therapy	64
Annual Cost of Immunosuppressant Drugs	64
The World Market for Immunosuppressant Drug Therapy	65
<i>TABLE 34 WORLDWIDE MARKET FOR IMMUNOSUPPRESSION IN SOLID ORGAN TRANSPLANT RECIPIENTS, THROUGH 2013</i>	65
<i>TABLE 35 GLOBAL SALES OF IMMUNOSUPPRESSIVES BY DRUG CATEGORY, THROUGH 2013 (\$ MILLIONS)</i>	65
<i>FIGURE 6 WORLDWIDE SALES OF IMMUNOSUPPRESSANTS BY CATEGORY, 2007-2013 (\$ MILLIONS)</i>	66
<i>TABLE 36 WORLDWIDE SALES OF BRAND NAME IMMUNOSUPPRESSANT DRUGS BY COMPANY, 2006 AND 2007 (\$ MILLIONS)</i>	66
PRODUCTS	67
ADDRESSING INFECTION	67
GRAFT-VERSUS-HOST DISEASE.....	67
POST-TRANSPLANT INFECTIONS.....	68
ViroPharma Incorporated	68

Cardiovascular Disease	69
<i>TABLE 37 COMMON POST-TRANSPLANT INFECTIONS</i>	69
<i>TABLE 38 TIMELINE FOR POST-TRANSPLANT INFECTION</i>	69
<i>TABLE 39 COMMON POST-TRANSPLANT DRUGS</i>	70
<i>TABLE 40 WORLD MARKET FOR ANTI-INFECTIVES USED FOR TRANSPLANT PATIENTS, THROUGH 2013 (\$ MILLIONS)</i>	70
POST-TRANSPLANT MONITORING	71
<i>TABLE 41 U.S. MARKET FOR POST-TRANSPLANT MONITORING, THROUGH 2013 (\$ MILLIONS)</i>	71
Cylex.....	71
 CHAPTER 6: PROCUREMENT AND HARVESTING	72
INCREASING SUPPLY	72
SUPPLY MANAGEMENT.....	73
REDUCING WASTE AND REJECTION	73
INCREASING THE HARVEST	74
<i>TABLE 42 RECOVERED ORGANS NOT USED BY TYPE, 2003–2006</i>	74
<i>TABLE 43 CONSENTED ORGANS NOT RECOVERED BY TYPE, 2003– 2006</i>	74
BETTER HARVESTING	75
DEFINITION OF BRAIN DEATH	75
PROTECTING HARVESTED ORGANS.....	75
HORMONAL RESUSCITATION	76
NON-HEART-BEATING DONORS	76
LESS WASTE.....	76
PRESERVATION.....	77
ORGAN PRESERVATION METHODS	78
Rinse and Preservation Solutions.....	78
<i>TABLE 44 MAJOR ORGAN PRESERVATION SOLUTIONS</i>	78
Celsior	79
Collins Solution.....	79
Custodiol	79
Hypothermosol.....	79
ViaSpan.....	79
Market for Preservation Solutions.....	80
<i>TABLE 45 NORTH AMERICAN AND WORLD MARKETS FOR ORGAN PRESERVATION SOLUTIONS (NOT INCLUDING THE PAPWORK COCKTAIL), THROUGH 2013 (\$ MILLIONS)</i>	80
Organ Preservation Products in Development.....	81
Human BioSystems	81
Trophic Solutions	81
Machine Perfusion.....	82
Waters Medical Systems	82
TransMedics, Inc.....	83
FIGHTING REJECTION	83

<i>TABLE 46 U.S. ORGAN RECIPIENTS WHO PREVIOUSLY HAD A TRANSPLANT: ALL ORGANS, 2003–2006</i>	83
CHAPTER 7: SOLID ORGAN TRANSPLANTATION	84
TRANSPLANT CENTERS	84
<i>TABLE 47 LEADING U.S. TRANSPLANT PROGRAMS BY TOTAL NUMBER OF PROCEDURES PERFORMED IN 2007</i>	84
TESTING	84
Blood Typing	85
Tissue Typing.....	85
Panel Reactive Antibodies (PRA).....	86
<i>TABLE 48 TISSUE TYPING TECHNOLOGIES</i>	86
Advances	86
<i>TABLE 49 SELECTED COMPETITORS IN THE HLA TYPING MARKET</i>	87
Plasmapheresis: Transplantation without Matching Antigens.....	88
KIDNEY	88
MARKET FOR KIDNEY TRANSPLANTS	89
<i>TABLE 50 U.S. MARKET FOR KIDNEY-ONLY TRANSPLANTATION, THROUGH 2013</i>	89
MARKET FOR IMMUNOSUPPRESSIVES FOR KIDNEY TRANSPLANTATION.....	89
<i>TABLE 51 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR KIDNEY TRANSPLANT PATIENTS, THROUGH 2013 (\$ MILLION)</i>	90
IMMUNOSUPPRESSION	90
Drugs Used for Induction.....	90
<i>TABLE 52 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN KIDNEY TRANSPLANTATION, 2003–2006 (%)</i>	91
Drugs Used for Maintenance Prior to Discharge	91
<i>TABLE 53 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BEFORE DISCHARGE AFTER KIDNEY TRANSPLANTATION, 2003–2006 (%)</i>	91
Drugs Used for Maintenance between Discharge and One- year Post-transplant	92
<i>TABLE 54 IMMUNOSUPPRESSION DRUG USE IN THE U.S. FOR MAINTENANCE BETWEEN DISCHARGE AND ONE-YEAR POST- TRANSPLANT FOR KIDNEY TRANSPLANTATION, 2002–2005 (%)</i>	92
ALTERNATIVES	92
Mechanical	92
Medical.....	93
Animal.....	93
Cellular	93
PANCREAS.....	93

MARKET FOR PANCREAS TRANSPLANTATION.....	93
<i>TABLE 55 U.S. MARKET FOR PANCREAS TRANSPLANTATION, THROUGH 2013.....</i>	<i>94</i>
WAITING LIST	94
<i>TABLE 56 U.S. PANCREAS WAITING LIST, THROUGH 2013.....</i>	<i>94</i>
IMMUNOSUPPRESSION	94
<i>TABLE 57 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR PANCREAS TRANSPLANT PATIENTS, THROUGH 2013.....</i>	<i>95</i>
Drugs Used for Induction	95
<i>TABLE 58 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN PANCREAS TRANSPLANTATION, 2003–2006 (%).....</i>	<i>96</i>
Drugs Used for Maintenance Prior to Discharge	96
<i>TABLE 59 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BEFORE DISCHARGE AFTER PANCREAS TRANSPLANTATION, 2003–2006 (%).....</i>	<i>96</i>
Drugs Used for Maintenance between Discharge and One-year Post-transplant	97
<i>TABLE 60 IMMUNOSUPPRESSION DRUG USE IN THE U.S. FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POST-TRANSPLANT FOR PANCREAS TRANSPLANTATION, 2002–2005 (%).....</i>	<i>97</i>
PREVALANCE OF DIABETES.....	97
ALTERNATIVES	98
HEART	98
<i>TABLE 61 U.S. HEART TRANSPLANT MARKET, THROUGH 2013 (\$ MILLIONS).....</i>	<i>99</i>
SUPPLY	99
Cultural Backlash.....	99
Accepting Brain Death is Crucial	100
WAITING LISTS.....	100
IMMUNOSUPPRESSION	101
<i>TABLE 62 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR HEART TRANSPLANT PATIENTS, THROUGH 2013</i>	<i>101</i>
Drugs Used for Induction	102
<i>TABLE 63 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN HEART TRANSPLANTATION, 2003–2006 (%).....</i>	<i>102</i>
Drugs Used for Maintenance Prior to Discharge	102
<i>TABLE 64 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN HEART TRANSPLANTATION, 2003–2006 (%).....</i>	<i>102</i>
<i>TABLE 64 (CONTINUED).....</i>	<i>103</i>
Drugs Used for Anti-rejection between Discharge and 1-year Post-transplant	103

<i>TABLE 65 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTI-REJECTION BETWEEN DISCHARGE AND 1-YEAR POST-TRANSPLANT IN HEART TRANSPLANTATION, 2002–2005</i>	103
INDICATIONS	104
<i>TABLE 66 LEADING CAUSES OF HEART FAILURE, 2002–2006 (%)</i>	104
TISSUE TYPING	104
PRESERVATION	105
ALTERNATIVES	105
LIVER.....	105
HISTORY.....	106
TRANSPLANT STATISTICS	106
ORGAN RECOVERY	106
THE MARKET FOR LIVER TRANSPLANTATION.....	107
<i>TABLE 67 U.S. LIVER TRANSPLANT MARKET, FIRST YEAR, THROUGH 2013 (\$ MILLIONS)</i>	107
DONORS.....	107
WAITING LISTS.....	107
<i>TABLE 68 REGIONAL GROWTH IN LIVER WAITING LISTS, THROUGH 2013</i>	108
IMMUNOSUPPRESSION	108
Drugs Used for Induction.....	108
<i>TABLE 69 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN LIVER TRANSPLANTATION, 2003–2006 (%)</i>	108
Drugs Used for Maintenance Prior to Discharge	109
<i>TABLE 70 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN LIVER TRANSPLANTATION, 2003–2006 (%)</i>	109
Drugs Used for Maintenance between Discharge and 1-Year Post-transplant.....	109
<i>TABLE 71 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POST-TRANSPLANT FOR LIVER TRANSPLANTATION, 2002–2005 (%)</i>	110
Drugs Used for Anti-rejection between Transplant and 1-Year Post-Transplant.....	110
<i>TABLE 72 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTI-REJECTION BETWEEN TRANSPLANT AND 1-YEAR POST-TRANSPLANT FOR LIVER TRANSPLANTATION, 2002–2005 (%)</i>	110
<i>TABLE 72 (CONTINUED)</i>	111
The Market for Immunosuppressive Drugs in Liver Transplantation.....	111
<i>TABLE 73 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR LIVER TRANSPLANT PATIENTS, THROUGH 2013 (\$ MILLIONS)</i>	111
INDICATIONS	111

Causes of Cirrhosis	112
TISSUE TYPING	112
ORGAN REJECTION	113
TABLE 74 LIVER TRANSPLANT SURVIVAL RATES IN THE U.S. AND	
EUROPE, 2003 (%)	113
LUNGS	113
TRANSPLANTATION STATISTICS	114
THE MARKET FOR LUNG TRANSPLANTATION	114
TABLE 75 U.S. LUNG TRANSPLANTATION MARKET, THROUGH	
2013 (\$ MILLIONS)	115
WAITING LISTS	115
INDICATIONS	115
TABLE 76 LEADING CAUSES OF CHRONIC LUNG FAILURE IN THE	
U.S., 2002–2006 (%)	116
DONATION	116
IMMUNOSUPPRESSION	116
TABLE 77 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES	
FOR LUNG TRANSPLANT PATIENTS, THROUGH 2013 (\$	
MILLIONS)	117
Drugs Used for Induction	117
TABLE 78 U.S. IMMUNOSUPPRESSION DRUG USE FOR	
INDUCTION IN LUNG TRANSPLANTATION, 2003–2006 (%)	117
Drugs Used for Maintenance Prior to Discharge	118
TABLE 79 U.S. IMMUNOSUPPRESSION DRUG USE FOR	
MAINTENANCE PRIOR TO DISCHARGE IN LUNG	
TRANSPLANTATION, 2002–2006 (%)	118
Drugs Used for Maintenance between Discharge and 1-	
Year Post-Transplant	118
TABLE 80 U.S. IMMUNOSUPPRESSION DRUG USE FOR	
MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POST-	
TRANSPLANT IN LUNG TRANSPLANTATION, 2003–2006 (%)	119
Drugs Used for Anti-rejection between Transplant and 1-	
Year Post-Transplant	119
TABLE 81 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTI-	
REJECTION BETWEEN TRANSPLANT AND 1-YEAR POST-	
TRANSPLANT IN LUNG TRANSPLANTATION, 2002–2005 (%)	119
TABLE 81 (CONTINUED)	120
REJECTION	120
TABLE 82 U.S. LUNG TRANSPLANT PATIENT AND GRAFT	
SURVIVAL RATES* (%)	120
ALTERNATIVES	120
HEART-LUNG	121
THE MARKET FOR HEART-LUNG TRANSPLANTATION	121

<i>TABLE 83 U.S. HEART-LUNG TRANSPLANT MARKET, THROUGH 2013 (\$ MILLIONS)</i>	121
IMMUNOSUPPRESSION	121
<i>TABLE 84 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR HEART-LUNG TRANSPLANT PATIENTS, THROUGH 2013 (\$ MILLIONS)</i>	122
Drugs Used for Induction	122
<i>TABLE 85 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN HEART-LUNG TRANSPLANTATION, 2003–2006 (%)</i>	122
Drugs Used for Maintenance Prior to Discharge	122
<i>TABLE 86 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN HEART-LUNG TRANSPLANTATION, 2003–2006 (%)</i>	123
Drugs Used for Maintenance between Discharge and 1-Year Post-Transplant.....	123
<i>TABLE 87 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POST-TRANSPLANT IN HEART-LUNG TRANSPLANTATION, 2002–2005 (%)</i>	123
Drugs Used for Anti-rejection between Transplant and 1-Year Post-Transplant.....	124
<i>TABLE 88 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTI-REJECTION BETWEEN TRANSPLANT AND 1-YEAR POST-TRANSPLANT IN HEART-LUNG TRANSPLANTATION, 2002–2005 (%)</i>	124
WAITING LISTS.....	124
<i>TABLE 89 U.S. HEART-LUNG WAITING LIST TRENDS, THROUGH 2013</i>	124
SURVIVAL RATES	125
<i>TABLE 90 U.S. HEART-LUNG TRANSPLANT PATIENT AND GRAFT SURVIVAL RATES (%)</i>	125
INTESTINE/SMALL BOWEL.....	125
HISTORY.....	125
TRANSPLANT TYPES	125
INDICATIONS	126
<i>TABLE 91 LEADING INDICATIONS FOR INTESTINE TRANSPLANT: ADULT PATIENTS</i>	126
<i>TABLE 92 LEADING INDICATIONS FOR INTESTINE TRANSPLANT: PEDIATRIC PATIENTS</i>	127
U.S. TRANSPLANTATION STATISTICS	127
<i>TABLE 93 U.S. SMALL BOWEL TRANSPLANTATION TRENDS, THROUGH 2013</i>	128
THE MARKET FOR INTESTINE TRANSPLANTATION	128

<i>TABLE 94 U.S. SMALL BOWEL TRANSPLANTATION MARKET, THROUGH 2013 (\$ MILLIONS)</i>	129
COUNTRIES WITH SMALL BOWEL/INTESTINES TRANSPLANT PROGRAMS.....	129
<i>TABLE 95 COUNTRIES WITH SMALL BOWEL TRANSPLANT PROGRAMS</i>	129
IMMUNOSUPPRESSION	129
<i>TABLE 96 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR HEART-LUNG TRANSPLANT PATIENTS, THROUGH 2013 (\$ MILLIONS)</i>	130
Drugs Used for Induction	130
<i>TABLE 97 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN INTESTINE TRANSPLANTATION, 2003–2006 (%)</i>	131
Drugs Used for Maintenance Prior to Discharge	131
<i>TABLE 98 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN INTESTINE TRANSPLANTATION, 2003–2006 (%)</i>	131
Drugs Used for Maintenance between Discharge and 1-Year Post-Transplant.....	132
<i>TABLE 99 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POST-TRANSPLANT IN INTESTINE TRANSPLANTATION, 2002–2005 (%)</i>	132
Drugs Used for Anti-rejection between Transplant and 1-Year Post-Transplant.....	132
<i>TABLE 100 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTI-REJECTION BETWEEN TRANSPLANT AND 1-YEAR POST-TRANSPLANT IN INTESTINE TRANSPLANTATION, 2002–2005 (%)</i>	132
<i>TABLE 100 (CONTINUED)</i>	133
INFECTION PROPHYLAXIS	133
ALTERNATIVES	133
CHAPTER 8: TISSUE TRANSPLANTATION.....	134
OVERVIEW.....	134
FEWER DONATIONS DUE TO PUBLIC MISTRUST.....	134
Compensation	134
Cosmetic Tissue Usage.....	135
CORNEA	135
HISTORY.....	135
GLOBAL ESTIMATES OF VISUAL IMPAIRMENT	136
CORNEAL TRANSPLANTS IN THE U.S.	136
<i>TABLE 101 U.S. CORNEAL TRANSPLANT MARKET, THROUGH 2013</i>	136
Waiting Lists.....	136
Waiting Lists: Other Countries.....	137
Tissue Testing.....	137
Preservation.....	138

Cryopreservation.....	138
Immunosuppression	138
ALTERNATIVES	138
BLOOD STEM CELLS	139
HISTORY.....	140
First Successful Transplant.....	140
Donor Registry Established.....	141
INDICATIONS	141
Cord Blood.....	142
Cord Blood Banking.....	142
PROCEDURE VOLUMES	143
<i>TABLE 102 PROJECTED U.S. HEMATOPOIETIC STEM CELL</i>	
<i>TRANSPLANT PROCEDURES, THROUGH 2013</i>	<i>143</i>
Autologous Versus Allogeneic	144
DONORS.....	144
<i>TABLE 103 BMDW MEMBER HOME COUNTRIES.....</i>	<i>145</i>
Blood Collection in the U.S.	145
<i>TABLE 104 NUMBER OF BONE MARROW DONORS, BY COUNTRY.....</i>	<i>146</i>
WAITING LISTS	147
REJECTION	147
IMMUNOSUPPRESSION	148
Enzo Biochem	148
MARKET FOR IMMUNOSUPPRESSANTS IN BLOOD STEM	
CELL TRANSPLANTS.....	148
<i>TABLE 105 U.S. MARKET FOR IMMUNOSUPPRESSIVE DRUG</i>	
<i>THERAPY FOLLOWING HEMATOPOIETIC TRANSPLANTATION,</i>	
<i>THROUGH 2013 (\$ MILLIONS).....</i>	<i>149</i>
CORD BLOOD.....	149
Increasing the Number of Cord Blood Cells.....	149
BONE GRAFT TRANSPLANTATION	150
HISTORY.....	150
GLOBAL BONE GRAFT MARKET	151
PROCEDURES.....	151
<i>TABLE 106 U.S. BONE GRAFT PROCEDURE VOLUMES BY TYPE OF</i>	
<i>GRAFT, THROUGH 2013</i>	<i>152</i>
<i>FIGURE 7 U.S. BONE GRAFT PROCEDURES, 2007-2013 (\$</i>	
<i>MILLIONS).....</i>	<i>152</i>
Spinal Fusion.....	152
Joint Replacement	153
INDICATIONS	153
ORTHOPEDIC IMPLANT MARKET.....	154
<i>TABLE 107 U.S. AND WORLDWIDE ORTHOPEDIC IMPLANT</i>	
<i>MARKET GROWTH, THROUGH 2013 (\$ MILLIONS).....</i>	<i>154</i>

<i>TABLE 108 U.S. ORTHOPEDIC IMPLANT MARKET BY NUMBER AND TYPE OF PROCEDURE, THROUGH 2013</i>	155
AUTOGRAFTS	155
Autografts (Continued).....	156
<i>TABLE 109 U.S. AND WORLD VALUES OF THE BONE GRAFTING MARKET, THROUGH 2013 (\$ MILLIONS)</i>	157
ALLOGRAFTS.....	157
Allografts (Continued).....	158
Risks Associated with Allografts	159
Products	159
Base Tissue	159
Demineralized Bone Matrix Products.....	159
Machined Implants.....	160
THE ORTHOBIOLOGICS MARKET	160
<i>TABLE 110 GLOBAL ORTHOBIOLOGICS MARKET, BY PRODUCT, THROUGH 2013 (\$ MILLIONS)</i>	161
The Market for Allografted Tissue.....	161
<i>TABLE 111 U.S. SALES OF BONE ALLOGRAFTS BY TYPE, THROUGH 2013 (\$ MILLIONS)</i>	161
<i>FIGURE 8 BONE ALLOGRAFT MARKET, THROUGH 2013 (\$ MILLIONS)</i>	162
BONE GRAFT SUBSTITUTES.....	162
<i>TABLE 112 COMPARISON OF BONE GRAFT MATERIALS</i>	163
<i>TABLE 113 SUBSTITUTE BONE GRAFT</i>	164
FACTOR-BASED BONE GRAFT SUBSTITUTES.....	164
Factor-Based Bone Graft ... (Continued).....	165
Bone Morphogenic Proteins (BMPs)	166
InductOs	167
INFUSE Bone Graft.....	167
OP-1 Implant.....	168
PREVENTING INFECTION	168
PRESERVATION	169
COMPETITION.....	170
VASCULAR TRANSPLANTATION.....	171
HISTORY.....	171
INDICATIONS	171
PROCEDURES.....	172
DONORS.....	172
HEART VALVES.....	172
HEART VALVE ALLOGRAFT MARKET.....	173
<i>TABLE 114 U.S. HEART VALVE TRANSPLANT MARKET, THROUGH 2013 (\$ MILLIONS)</i>	173
TISSUE TESTING	174
SYNTHETICS	174

XENOGRAFTS	175
ADVANCES	175
Symetis.....	175
Edwards Life Sciences	176
BETTER MONITORING	176
TISSUE VALVES GAIN POPULARITY.....	176
MAJOR COMPETITORS.....	176
VASCULAR GRAFTS	177
Indications	177
Waiting List	178
Products	178
ALTERNATIVES TO VASCULAR TRANSPLANTATION	178
SKIN TRANSPLANTATION.....	178
<i>TABLE 115 U.S. MARKET FOR HUMAN SKIN-BASED PRODUCTS,</i>	
<i>THROUGH 2013.....</i>	<i>179</i>
HISTORY.....	180
MARKET POTENTIAL.....	181
INDICATIONS	181
Burns.....	181
Other Injuries	182
Cosmetic Surgery.....	183
Wounds.....	183
Venous Ulcers	183
<i>TABLE 116 ESTIMATED INCIDENCE OF VENOUS ULCERS IN THE</i>	
<i>U.S. OVER-64 POPULATION, THROUGH 2013.....</i>	<i>183</i>
Diabetic Ulcers.....	184
<i>TABLE 117 ESTIMATED U.S. INCIDENCE OF DIABETIC FOOT</i>	
<i>ULCERS, THROUGH 2013 (MILLIONS).....</i>	<i>184</i>
Pressure Ulcers	184
Urinary Incontinence and Other Uses.....	185
Collagen Meniscus Implant.....	185
REJECTION.....	185
TISSUE TESTING	185
PRESERVATION	186
CELLULAR TRANSPLANTATION.....	186
HISTORY.....	187
INDICATIONS	187
TYPES OF CELLS	188
DONORS.....	188
REJECTION.....	188
GOVERNMENT REGULATIONS.....	189
ALTERNATIVES	189
CHAPTER 9: ALTERNATIVES TO DONOR TRANSPLANTATION	190
ALTERNATIVES TO CORNEAL TRANSPLANTATION	190

SURGICAL.....	190
ARTIFICIAL CORNEAS.....	191
RETINAL TRANSPLANTS	191
CELLULAR TRANSPLANTS.....	192
ELECTRONIC IMPLANTS	192
ALTERNATIVES TO INTESTINAL TRANSPLANTATION	193
MEDICAL.....	193
CELLULAR	193
ALTERNATIVES TO PANCREAS TRANSPLANTATION	193
MEDICAL.....	193
Islet Cell Transplantation	193
Islet Cell Transplantation (Continued).....	194
Drawbacks.....	195
Cell Encapsulation.....	195
ReNeuron	195
Bioartificial Pancreas	195
Cerco Medical.....	196
Cultured Stem Cells	197
Diminished Need for Transplantation in the Future.....	197
COSTS	197
ALTERNATIVES TO HEART TRANSPLANTATION	197
MEDICAL.....	197
Fibroblast Growth Factors	198
CardioVascular BioTherapeutic, Inc.....	199
Endovasc, Ltd.....	200
Gene Therapy.....	200
Naked Plasmid DNA Transfer	201
Adenoviral Vectors.....	201
XENOTRANSPLANTATION	202
SURGICAL.....	203
Laser Revascularization	203
Mitral Valve Repair.....	203
CARDIAC SUPPORT DEVICES	204
Passive Support Systems	204
MECHANICAL.....	205
REGENERATION INSTEAD OF REPLACEMENT	205
Biophan	205
MECHANICAL ORGANS.....	206
VAD Market.....	207
VAD costs	207
<i>TABLE 118 GLOBAL MARKET FOR VADS, THROUGH 2013 (\$</i>	
<i>MILLIONS)</i>	<i>208</i>
<i>TABLE 119 U.S. MARKET FOR VADS USED AS DESTINATION</i>	
<i>THERAPY, THROUGH 2013 (\$ MILLIONS)</i>	<i>208</i>

DeBakey LVAS	209
HeartMate.....	209
Incor LVAD, Excor VAD.....	210
Novacor	210
VAD DEVELOPMENT IN THE U.S.	211
<i>TABLE 120 LEFT VENTRICULAR ASSIST DEVICES IN DEVELOPMENT</i>	<i>211</i>
Arrow International	211
CardiacAssist	212
Jarvik	212
Ventracor	212
TOTAL ARTIFICIAL HEARTS	212
AbioMed	212
CardioWest.....	213
OTHER CARDIAC ASSIST DEVICES IN DEVELOPMENT.....	213
CELLULAR THERAPY	214
Bioheart.....	214
ALTERNATIVES TO LIVER TRANSPLANTATION	215
MEDICAL.....	215
Vertex Pharmaceuticals	215
ARTIFICIAL LIVERS	215
CHEMICAL/MECHANICAL AND/OR BIOARTIFICIAL LIVERS	216
<i>TABLE 121 INDICATIONS FOR THE BIOARTIFICIAL LIVER</i>	<i>216</i>
Chemical/Mechanical...(Continued)	217
<i>TABLE 122 BIOARTIFICIAL LIVERS IN DEVELOPMENT</i>	<i>218</i>
Bioartificial Liver Support System	218
ELAD.....	219
Modular Extracorporeal Liver Support (MELS)	219
Molecular Adsorption Recycling System (MARS)	219
RELATIVE COSTS	220
ALTERNATIVES TO LUNG TRANSPLANTATION.....	220
MEDICAL.....	220
SURGICAL	220
ALTERNATIVES TO BONE GRAFTS	221
MEDICAL.....	221
SYNTHETIC MATERIALS	222
Orthovita.....	222
Spine Wave	223
ReGen Biologics	223
ALTERNATIVES TO VASCULAR TRANSPLANTATION	223
ANIMAL	223
Stentless Valves.....	224
Calcification	224

SURGICAL.....	225
Angioplasty and Stents	225
MEDICAL.....	226
MECHANICAL/SYNTHETIC.....	226
ALTERNATIVES TO VASCULAR TRANSPLANTATION	226
TISSUE ENGINEERING OF VASCULAR GRAFTS.....	226
GENE THERAPY	227
ALTERNATIVES TO SKIN TRANSPLANTATION	228
ANIMAL-BASED PRODUCTS.....	228
Biobrane.....	228
OaSIS	229
GROWTH FACTORS	229
ARTIFICIAL SKIN/SKIN REPLACEMENT PRODUCTS.....	229
AlloDerm	229
Apligraf	230
Cymetra.....	230
Dermagraft.....	230
Epicel.....	231
Integra Products	231
OrCel	231
TransCyte	232
MANUFACTURERS OF ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS.....	233
<i>TABLE 123 MANUFACTURERS OF ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS</i>	<i>233</i>
THE MARKET FOR ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS.....	233
<i>TABLE 124 ESTIMATED WORLDWIDE MARKET FOR ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS, THROUGH 2013 (\$ MILLIONS).....</i>	<i>233</i>
<i>TABLE 125 ESTIMATED U.S. MARKET FOR ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS, THROUGH 2013 (\$ MILLIONS)</i>	<i>234</i>
PRODUCTS IN DEVELOPMENT	234
Altex Plus, Ltd.....	234
Cytomedix	234
Geron.....	234
OTHER RESEARCH.....	235
REGULATION	235
CHAPTER 10: COMPANY PROFILES	236
ABIOMED, INC.	236
BUSINESS OVERVIEW.....	236
FINANCIAL INFORMATION.....	236
PRODUCTS.....	236
ARBIOS SYSTEMS, INC.....	237

BUSINESS OVERVIEW.....	237
FINANCIAL INFORMATION.....	237
PRODUCTS.....	237
ARROW INTERNATIONAL.....	237
BUSINESS OVERVIEW.....	237
FINANCIAL INFORMATION.....	238
PRODUCTS.....	238
ASTELLAS PHARMA, INC.....	238
BUSINESS OVERVIEW.....	238
FINANCIAL INFORMATION.....	238
CRYOLIFE, INC.....	239
BUSINESS OVERVIEW.....	239
FINANCIAL INFORMATION.....	239
PRODUCTS.....	239
DEPUY ORTHOPEDICS.....	240
BUSINESS OVERVIEW.....	240
FINANCIAL INFORMATION.....	240
PRODUCTS.....	240
EDWARDS LIFESCIENCES.....	240
BUSINESS OVERVIEW.....	241
FINANCIAL INFORMATION.....	241
PRODUCTS.....	241
EXACTECH.....	241
BUSINESS OVERVIEW.....	242
FINANCIAL INFORMATION.....	242
PRODUCTS.....	242
FORTICELL BIOSCIENCE.....	242
BUSINESS OVERVIEW.....	242
FINANCIAL INFORMATION.....	243
PRODUCTS.....	243
FRESENIUS MEDICAL CARE AG & CO. KGAA.....	243
BUSINESS OVERVIEW.....	243
FINANCIAL INFORMATION.....	244
PRODUCTS.....	244
GENZYME.....	244
BUSINESS OVERVIEW.....	244
FINANCIAL INFORMATION.....	244
PRODUCTS.....	245
HEMOCLEANSE, INC.....	245
BUSINESS OVERVIEW.....	245
FINANCIAL INFORMATION.....	246
PRODUCTS.....	246
JOHNSON & JOHNSON.....	246
BUSINESS OVERVIEW.....	246

FINANCIAL INFORMATION.....	247
PRODUCTS	247
KIADIS PHARMA.....	247
BUSINESS OVERVIEW.....	247
FINANCIAL INFORMATION.....	247
PRODUCTS.....	248
KINETIC CONCEPTS, INC (KCD).....	248
BUSINESS OVERVIEW.....	248
FINANCIAL INFORMATION.....	249
PRODUCTS	249
LIFEBLOOD MEDICAL, INC.....	250
BUSINESS OVERVIEW.....	250
FINANCIAL INFORMATION.....	250
PRODUCTS	250
LIFECYCLE CORP. (SEE KINETIC CONCEPTS, INC).....	251
LIFECYCLE PHARMA A/S.....	251
BUSINESS OVERVIEW.....	251
FINANCIAL INFORMATION.....	251
PRODUCTS	251
LIVING CELL TECHNOLOGIES, LTD.....	252
BUSINESS OVERVIEW.....	252
FINANCIAL INFORMATION.....	252
PRODUCTS	252
MEDTRONIC, INC.....	253
BUSINESS OVERVIEW.....	253
FINANCIAL INFORMATION.....	253
PRODUCTS	254
NOVARTIS AG.....	255
BUSINESS OVERVIEW.....	255
FINANCIAL INFORMATION.....	255
PRODUCTS.....	255
ON-X LIFE TECHNOLOGIES, INC.....	256
BUSINESS OVERVIEW.....	256
FINANCIALS	256
PRODUCTS	256
ORGANOGENESIS, INC.	256
BUSINESS OVERVIEW.....	257
FINANCIALS	257
PRODUCTS	257
OSTEOTECH.....	257
BUSINESS OVERVIEW.....	257
FINANCIAL INFORMATION.....	258
PRODUCTS.....	258
PDL BIOPHARMA.....	258

BUSINESS OVERVIEW.....	258
FINANCIAL INFORMATION.....	259
PRODUCTS.....	259
ROCHE PHARMACEUTICALS.....	259
BUSINESS OVERVIEW.....	259
FINANCIALS.....	259
PRODUCTS.....	260
SORIN GROUP, S.P.A.....	260
BUSINESS OVERVIEW.....	260
FINANCIALS.....	261
PRODUCTS.....	261
ST. JUDE MEDICAL.....	261
BUSINESS OVERVIEW.....	261
FINANCIALS.....	262
PRODUCTS.....	262
STRYKER CORPORATION.....	262
BUSINESS OVERVIEW.....	263
FINANCIAL INFORMATION.....	263
PRODUCTS.....	263
SYNCARDIA SYSTEMS, INC.....	264
BUSINESS OVERVIEW.....	264
FINANCIALS.....	264
PRODUCTS.....	264
SYTHES (US).....	265
BUSINESS OVERVIEW.....	265
FINANCIAL INFORMATION.....	265
PRODUCTS.....	265
TRANSMEDICS, INC.....	266
BUSINESS OVERVIEW.....	266
FINANCIALS.....	266
PRODUCTS.....	266
THORATEC CORP.....	267
BUSINESS OVERVIEW.....	267
FINANCIAL INFORMATION.....	267
PRODUCTS.....	267
VENTRACOR.....	268
BUSINESS OVERVIEW.....	268
FINANCIAL INFORMATION.....	268
PRODUCTS.....	269
VIROPHARMA, INC.....	269
BUSINESS OVERVIEW.....	269
FINANCIAL INFORMATION.....	269
PRODUCTS.....	269
WORLD HEART CORP.....	270

BUSINESS OVERVIEW.....	270
FINANCIAL INFORMATION.....	270
PRODUCTS.....	270
WYETH	271
BUSINESS OVERVIEW.....	271
FINANCIAL INFORMATION.....	271
PRODUCTS.....	271